MODELING REVOLUTION
Patient-derived organoids and organ-on-chip platforms enable disease modeling with unprecedented human relevance. Unlike immortalized cell lines or genetically modified animals, these systems capture patient-specific genetic backgrounds, disease heterogeneity, and the complex cellular microenvironment that drives pathophysiology—enabling precision medicine approaches to drug development.
DISEASE CATEGORIES
- Oncology: Patient-derived tumor organoids maintain genetic heterogeneity for drug sensitivity testing
- Neurodegeneration: Brain organoids model Alzheimer's, Parkinson's, and ALS pathology
- Metabolic Disease: NASH/NAFLD liver models with steatosis, inflammation, and fibrosis
- Genetic Disorders: iPSC-derived organoids from patients with cystic fibrosis, muscular dystrophy
- Inflammatory Disease: IBD gut organoids and rheumatoid arthritis synovium-on-chip
TECHNOLOGY PLATFORMS
- Tumor Organoids: Crown Bioscience HuTumorX with 3,000+ PDX-derived models
- Brain Organoids: Sergiu Pașca assembloids modeling cortico-striatal circuits
- Liver Disease: InSphero NASH models with stellate cell activation and fibrosis
- Genetic Disease: HUB Organoids cystic fibrosis panel (70+ CFTR mutations)
CLINICAL TRANSLATION
Disease models derived from patient tissue predict individual drug responses with 80%+ accuracy in oncology. Co-clinical trials using patient-matched organoids enable real-time treatment optimization, while biobanks spanning diverse genetic backgrounds support inclusive drug development across populations.